Testing and Isolation Efficacy: Insights from a Simple Epidemic Model

June 1, 2021

1 Abstract

16

19

21

22

[BMB: abstract needs another editing pass, skipping for now]

The effect of testing processes, including testing and test reporting, on epidemic dynamics, involving infection and recovery, can be studied at the individual level or the community level (e.g., nursing homes, long-term-care facilities, etc.). Gaining insights to determine the sensitivity of the epidemic dynamics with respect to the testing processes will depend on underlying factors including the level of focus (individual or community), assumptions (model), and the interplay between these factors. In particular, fast testing and test reporting may be beneficial at the community-level, supported by many studies, as it gives a rapid assessment of the situation, identifies hot spots, and may enable rapid contact-tracing. However, the potential advantage of a slow rate of test return on the dynamics of an epidemic is real, often neglected, and needs to be quantified. At the individual level, this advantage can manifest in the following sense: individuals awaiting their test results or who have tested positive may partially or fully self-isolate, thus reducing or eliminating their potential in the transmission process. In this paper, we investigated this individual-level effect of testing processes on the epidemic dynamics by developing a SIR-type model. Although the model development was motivated by the COVID-19 epidemic, the model has general epidemiological and testing structures. The realistic components of the model include per capita testing intensity, test sensitivity and specificity, rate of test return, and isolation efficacy (i.e., reduction of the transmission probability by isolating individuals). The novel component is the compartmentspecific relative testing weights, which reflect the testing strategies – surveillance, diagnosis, or control. Here, we compare two testing strategies, random vs. targeted, and concluded that increasing testing "focus" from random to targeted always decreases \mathcal{R}_0 . Further, the following processes always decreases \mathcal{R}_0 ; increasing the isolation efficacy parameters for tested and confirmed individuals, higher testing intensity if testing is random or testing intensity is small, and a higher rate of test return if the isolation efficacy for tested-awaiting individuals is low.

2 Introduction

The observed dynamics of the COVID-19 epidemic have been driven both by epidemiological processes (infection and recovery) and by testing processes (testing and test reporting). In addition to shaping epidemic observations (via case reports), testing processes also alter epidemiological dynamics. Because individuals with confirmed infections (positive tests) are likely to self-isolate, and individuals who are awaiting the results of a test may also do so (possibly to a lesser extent), testing will generally increase the number of people who are isolating and hence reduce epidemic growth rates. We developed a mechanistic model that incorporates epidemic processes and testing in order to explore the effects of testing and isolation on epidemic dynamics.

If testing influences behavior, then epidemic dynamics will depend on who gets tested. The impacts of testing will depend both on testing intensity (tests performed per day) and on how strongly testing is focused on people who are infectious. This level of focus depends in turn on the purpose and design of testing programs. When testing is done for the purposes of disease surveillance (Foddai et al., 2020) tests are typically assigned randomly (or using a stratified random design) across the population in order to make an unbiased assessment of population prevalence.

Over the course of the COVID-19 pandemic, however, the vast majority of testing has been done with other goals – primarily diagnostic (determining infection status for clinical purposes), or for control (determining infection status in order to isolate cases that have been found by contact tracing), which we characterize as targeted testing strategies. In these cases, testing probabilities vary widely across epidemiological compartments; in our dynamical model, we will characterize these probabilities by assigning a per capita testing weight to each compartment that determines the relative probability that an individual in that compartment will be selected for testing (see Methods).

Diagnostic testing focuses on people with infection-like symptoms; thus the relative testing weights for infected people will depend on the relative probability of infected people having symptoms. For COVID-19 infection, the testing weights will depend on the proportion of asymptomatic infections, the time spent pre-symptomatic vs. symptomatic during the course of an infection, and on the incidence of COVID-19-like symptoms among people in the population *not* infected with COVID-19. Testing for epidemic control focuses on known contacts of infected people; in this case the testing weights for infected vs. uninfected people will depend on the probability of infection given contact, as well as the effectiveness of the system for identifying suspicious contacts.

As epidemiologists, we want to know whether an epidemic will initially grow exponentially following its introduction in a susceptible population. In mathematical epidemiology, we determine this outcome by studying the basic reproduction number \mathcal{R}_0 , defined as the expected number of secondary infections arising from a typical infective individual in a completely susceptible population (Dietz, 1993). In the early stages of an epidemic the number of infected individuals is expected to grow exponentially over time when $\mathcal{R}_0 > 1$. Although the value of \mathcal{R}_0 cannot completely characterize the dynamics of even the simplest epidemic model (Shaw and Kennedy, 2021), it does give a simple and widely accepted index for the difficulty of control, as well as an indication of the likely final size of an epidemic (Ma and Earn, 2006).




Figure 1: Flowchart of the SIR (Susceptible-Infectious-Recovered) model, A1. The disease-based status of a compartment X ($X \in \{S, I, R\}$) is combined with the testing status including $X_{\rm u}$, $X_{\rm p}$, $X_{\rm n}$ and $X_{\rm c}$, for untested, waiting-for-positive, waiting-for-negative, or confirmed positive, respectively. The force of infection is denoted by Λ (Eq. (3)); γ is the recovery rate; ω is the rate of test return; and F_X (Eq. (2)) and p_X represent the per capita testing rate and the sensitivity (probability of positive tests), respectively, for compartment X. For further description of the parameters see Table 1. Note that there is a slight mismatch in the top-to-bottom order of the testing-based compartments of each disease-based compartment X between this flowchart and the model equations (A1); here we have switched $X_{\rm u}$ and $X_{\rm n}$ for visual clarity.

In order to understand the effect of testing processes on an epidemic dynamics, we developed a mechanistic SIR-type model with epidemic and testing components. This model provides a sensible platform to link the modeling of epidemic and testing components and study their interaction. Here, we studied the the effect of testing intensity, rate of test return and the isolation efficacy in reduction of the probability of transmission on the epidemic dynamics when different levels of testing focus (from random to highly targeted) are in place.

3 Methods

We developed a deterministic model, Eqs. (A1), which groups individuals based on disease status and testing status. Disease states include Susceptible, Infectious and Recovered; testing status categorizes people as untested, waiting-for-positive, waiting-for-negative, or confirmed positive (Fig. 1). The testing status of an individual in a given disease compartment X (where $X \in \{S, I, R\}$) is denoted by a subscript, namely X_u , X_p , X_n and X_c , for untested, waiting-for-positive, waiting-for-negative, or confirmed positive, respectively. Further, two 'accumulator' compartments, N and P, are included in order to collect cumulative reported negative or positive tests. The model equations and details of calculation of the basic reproduction number \mathcal{R}_0 are presented in the appendix (Sec. 5.1).

Table 1 defines the model parameters, which are generally per capita flows between compartments, or modifiers to these flow rates. The novel component of the model lies in the compartment-specific relative testing weights w_S , w_I and w_R ; these give the relative rates at

which people in the S, I, and R compartments are tested, respectively. Thus, we can specify different levels of testing focus from random (all weights equal) to highly targeted (higher weights in more intensively tested compartments). For example, $w_I/w_S = 3$ means that infected individuals are tested at three times the *per capita* rate of susceptible individuals.

94

96

104

105

106

107

109

113

114

115

116

117

In order to allow parameterization of the model by the total (overall) per capita testing rate, we define the weighted size of the testing pool $W = w_S S_u + w_I I_u + w_R R_u$, and calculate a scaling parameter for testing as:

$$\sigma = \frac{\rho N_0}{W},\tag{1}$$

where ρ is the *per capita* testing intensity for the population, defined as the number of daily tests administered in a population of size N_0 . Thus, the *per capita* testing rate for compartment X is

$$F_X = \sigma w_X$$
, where $X \in \{S, I, R\}$. (2)

For a highly sensitive test, infected people typically flow through to the "confirmed positive" (I_c, R_c) compartments and are thus unavailable for further testing. Over the course of the epidemic, a sufficiently large fixed testing rate as specified in (1) can exhaust the pool of people available for testing, leading to a singularity when too few people are left untested to support the specified rate. Although this phenomenon does not affect our analysis of \mathcal{R}_0 , it can affect the temporal dynamics (in the appendix we present an adjustment to the model that solves this problem).

The classical SIR model assumes a well-mixed population; homogeneity of the population (i.e., all individuals are equally susceptible and equally infectious with the same recovery rate when infected); exponentially distributed duration of infection; and large population size (Keeling and Rohani, 2011). In addition to these standard assumptions, our model assumes:

(i) there is a single force of infection (new cases per unit time), Λ , defined as

$$\Lambda = \frac{\beta}{N_0} (I_u + (1 - \theta_w)(I_n + I_p) + (1 - \theta_c)I_c),$$
 (3)

with transmission rate β ; $\theta_{\rm w}$ is the isolation efficacy (reduction of the probability of transmission) for individuals waiting for test results, while $\theta_{\rm c}$ is the isolation efficacy for individuals who have received a positive test ("confirmed positive": Table 1). Susceptible individuals who are waiting for test results experience an additional transmission factor of $1 - \theta_{\rm w}$ (Fig. 1).

(ii) confirmed-positive individuals isolate more effectively than those awaiting test results, i.e.

$$0 < \theta_{\rm w} < \theta_{\rm c} < 1$$
.

For simplicity we assume that tests are perfectly specific — uninfected individuals never test positive $(p_s = 0)$. Thus there are no waiting-for-positive or confirmed-positive susceptible individuals (we assume that these states are also absent from the initial conditions, i.e. $S_p(0) = S_c(0) = 0$), which reduces the number of model states from 12 to 10.

Symbol	Description	Unit	Value
N_0	Total population size	people	10^{6}
ω	Rate of test return, i.e., rate of onward flow from "waiting" to "confirmed" or "untested" compartments	1/day	-
γ	Recovery rate	$1/\mathrm{day}$	1/3
ρ	per capita testing intensity	1/day	-
$ heta_{ m w}$	Isolation efficacy (reduction of the transmission probability) for "waiting" individuals	-	-
$ heta_{ m c}$	Isolation efficacy for "confirmed positive" individuals	-	-
β	Transmission rate	$1/\mathrm{day}$	0.339
Λ	Force of infection	1/day	-
p_S	Probability of positive tests for $S (= 1 - \text{specificity})$	-	0
p_I	Probability of positive tests for I (= sensitivity)	-	1
p_R	Probability of positive tests for $R (= 1 - \text{specificity})$	-	0.5
w_S, w_I, w_R	Relative testing weights	-	Random: {1,1,1} Targeted: {0.3,1,1}

Table 1: Parameters of the model (A1).

The Disease-Free Equilibrium (DFE) for the SIR model (Eqs. A1) is found by setting the infected compartments to 0 and solving for the unknowns. The DFE is

$$S_{\rm n}^* = \frac{\rho}{\omega} N_0, \ S_{\rm u}^* = \frac{\omega - \rho}{\omega} N_0, \ \text{and} \ I_j = R_j = 0 \text{ for all } j.$$
 (4)

The corresponding *per capita* testing rate (Eq. 2) for the infected compartment I at DFE is one of the key analysis parameters and can be simplified as

$$\hat{F}_I = (\omega \rho / (\omega - \rho)) w_I / w_S \quad . \tag{5}$$

The basic reproduction number, \mathcal{R}_0 , was calculated by using the next-generation matrix method (van den Driessche and Watmough, 2002). We present \mathcal{R}_0 in the following form.

$$\mathcal{R}_0 = \frac{\beta}{\gamma} (1 - \Delta),\tag{6}$$

where the term $\frac{\beta}{\gamma}$ is the classical basic reproduction number for a SIR model without testing and isolation (Keeling and Rohani, 2011), and the positive quantity Δ is the effectiveness of control due to testing and isolation processes defined as

$$\Delta = \frac{1}{CN_0} \left(C_1 S_{\rm u}^* + \left(C_2 (1 - \theta_{\rm w}) + C \theta_{\rm w} \right) S_{\rm n}^* \right), \tag{7}$$

[BMB: super-fussy, but: I don't think we should introduce explicit thinspaces everywhere; why not let TeX do the typesetting itself? Do we really prefer more compact equations, and if so is there a package that will just change the appropriate settings globally?][Ali: are we talking about

,?] where

133

134

135

136

138

139

141

$$C = (\omega + \gamma) \Big(\gamma(\omega + \gamma) + (\gamma + \omega p_I) \hat{F}_I \Big), \tag{8}$$

$$C_1 = (\omega + \gamma)(\theta_{\mathbf{w}}\gamma + \theta_{\mathbf{c}}\omega p_I)\hat{F}_I, \tag{9}$$

$$C_2 = \left(\omega\gamma(1+p_I)\hat{F}_I + \gamma^2(\omega+\gamma+\hat{F}_I)\right)\theta_{\rm w} + \omega^2 p_I \hat{F}_I \theta_{\rm c}.$$
 (10)

Further details of derivation of \mathcal{R}_0 are provided in appendix, Sec. 5.1. The explicit formula of \mathcal{R}_0 enables us to study the effects of testing and isolation parameters on \mathcal{R}_0 both analytically and via numerical solutions. We are specifically interested in parameters that could be manipulated by public health policy: isolation efficacy, θ_c and θ_w ; per capita testing intensity, ρ ; and the rate of test return, ω . In particular, we look at the partial derivatives of Δ with respect to these parameters (Sec. 5.2). We derived general expressions for these derivatives. However, we analyzed the effect of ω on \mathcal{R}_0 for the special case of low testing intensity. Specifically, by making the restriction $\rho \ll 1$, we are able to Taylor-expand Δ at $\rho = 0$ and analyze the resulting simplified derivatives to illustrate a surprising non-monotonic relationship between \mathcal{R}_0 and ω .

The analytical calculation of the next-generation matrix and simplification of the \mathcal{R}_0 expression was carried out in Maple (Maplesoft, 2010). We used R (R Core Team, 2020) for

numerical solutions, in particular for plotting the contours of Δ (Eq. (7)) over a range of parameters. We computed the values and contours of Delta at both low (Fig. 2) and high (Fig. 3) testing intensities, and for both random testing ($w_S = w_I = w_R = 1$) and targeted testing ($w_S = 0.3$; $w_I = w_R = 1$).

The low-testing case Fig. 2 reflects the case where rho is small relative to the population size. Specifically, $\rho \in [0,0.013]$, and test return rate $\omega \in [1/12,2]$. This testing intensity reflects realistic testing rates during the COVID-19 pandemic, i.e. a maximum of 1.3% of the population per day, giving a maximum of 10000 tests/day in a population of size $N_0 = 10^6$ (this is approximately four times the maximum testing rate in Ontario, Canada in mid-2021). The less realistic high-testing case Fig. 3 is included to highlight the occurrence of non-monotonic changes in \mathcal{R}_0 with respect to ρ . In Fig. 3 the maximum capacity of ρ is larger relative to the population size, $\rho \in [0, 1/5)$ and the test return rate $\omega \in [1/5, 2]$; these values are clearly unrealistic for a large population but might be relevant for some population undergoing focused testing, such as a sports league or university. The critical contour of $\Delta = 1 - \frac{\gamma}{\beta}$, corresponding to the threshold $\mathcal{R}_0 = 1$, is shown as a dotted line in Fig. 2 and Fig. 3; combinations of ρ and ω that lie above this critical contour will control the epidemic. The implied baseline value of $\mathcal{R}_0 = \frac{\beta}{\gamma}$ in these figures is ≈ 1.017 , corresponding to a case where the epidemic spreads slowly even in the absence of testing and tracing. [BMB: how did we choose this particular value?][Ali: I was thinking of "critical" $\mathcal{R}_0 = 1$ and wanted to have the baseline in the plot. [BMB: JD wonders whether we really need the "critical" $\mathcal{R}_0 = 1$ contour or not; any contour will do to illustrate a threshold level of testing intensity, and the fact that $\mathcal{R}_0 = 1$ falls in the middle of our range is a bit arbitrary (i.e. the fact that testing can control the epidemic depends on the baseline \mathcal{R}_0 value we have chosen). (I know it was my idea in the first place, but maybe we could dispense with it?)][Ali: agree, the plots are updated.]

4 Results and discussion

144

145

146

148

150

151

153

154

155

156

157

158

159

160

162

164

166

173

178

179

We can use the formula for \mathcal{R}_0 (6) to make a number of straightforward conclusions about parameters whose effects on \mathcal{R}_0 are monotonic (i.e. the partial derivative of Δ has a consistent sign: Sections 5.2, 5.3, 5.5).

- 1. Increasing isolation efficacy for waiting (θ_w) and confirmed-positive (θ_c) individuals always decreases \mathcal{R}_0 (Eqs. A13, A16, A18);
- 2. Higher testing intensity ρ decreases \mathcal{R}_0 if testing is random (all w_X equal) or testing intensity (ρ) is small (Eq. A20).
- 3. Increasing the rate of test return (ω) always decreases \mathcal{R}_0 if waiting individuals do not isolate $(\theta_w = 0)$ (Eq. A23).
 - 4. Increasing testing focus, i.e. changing the testing weights from random $(w_S = w_I)$ toward targeted $(w_S < w_I)$, always decreases \mathcal{R}_0 (Eq. A24).




Figure 2: A comparison of effectiveness control on \mathcal{R}_0 at low level of per capita testing intensity ρ . Numerical evaluation of the effectiveness control parameter, Δ (Eq. 5.2), with respect to changes in testing and isolation. Parameter values (Table 1): $\beta = 0.339 \text{ day}^{-1} \ \gamma = 1/3 \text{ day}^{-1}; \ \omega \in [1/12, 2] \text{ day}^{-1}; \ \rho \in [0, 0.013] \text{ day}^{-1}; \ \theta_w \text{ and } \theta_c \text{ vary between 0 (no effect of isolation) and 1 (complete elimination of transmission); <math>p_S = 0, p_I = 1$ and $p_R = 0.5$. Contours of Δ are plotted for (a) random testing ($w_S = w_I = w_R = 1$) and (b) targeted testing ($w_S = 0.3; \ w_I = w_R = 1$). The baseline basic reproduction number \mathcal{R}_0 and the doubling time r, i.e. β/γ and $\beta - \gamma$ respectively, are approximately 1.017 and 0.006 in this simulation.

However, there are also two specific cases where Δ changes non-monotonically, in counterintuitive directions, as a function of testing and isolation parameters.

- When waiting individuals do not isolate (e.g. $\theta_w = 0$, top row of Fig. 2), increasing testing delays (i.e. decreasing ω) increases \mathcal{R}_0 , as we might expect: Δ decreases a larger region of the parameter space has $\mathcal{R}_0 > 1$, and the threshold testing intensity required to control the epidemic increases as we move to the right within each plot in this row. However, when waiting individuals are at least partially isolated ($\theta_w > 0$), we typically see the opposite effect: longer testing delays lead to less transmission. This is because returning negative tests leads people to stop distancing; this applies both to susceptibles, and to infectious people who receive negative test results because they were sampled when susceptible (or because of imperfect test sensitivity, which we have not considered in our analysis). For small but non-zero waiting-isolation levels (e.g. $\theta_w = 0.25$, second row from top), with high levels of confirmed isolation ($\theta_c \geq 0.5$), increasing testing delays initially decreases Δ , then increases it as the testing delays pass a threshold value of approximately 2–5 days.
- Fig. 2 also shows that greater testing intensity (increasing ρ) generally increases the effectiveness of control (moving up in each panel). This relationship can be reversed,




Figure 3: A comparison of effectiveness control on \mathcal{R}_0 at high level of per capita testing intensity ρ . We numerically evaluate the effectiveness control parameter, Δ (Eq. 5.2), with respect to testing and isolation. We use the following parameters (see Table 1 for a brief description): $\omega \in [1/5, 2]$ 1/day, $1/\gamma = 3$ days, $\rho \in [0, 1/5)$ 1/day, θ_w and θ_c vary between 0 and 1 with 0 for no effect and 1 for full effect of isolation on the transmission probability, $\beta = 0.339$ 1/day, $p_S = 0$, $p_I = 1$ and $p_R = 0.5$. Contours of Δ are plotted for two testing strategies identified by a set of relative testing weights; (a) random testing where $w_S = w_I = w_R = 1$ and (b) targeted testing where $w_S = 0.3$ and $w_I = w_R = 1$. The baseline basic reproduction number \mathcal{R}_0 and the doubling time r, i.e. β/γ and $\beta-\gamma$ respectively, are approximately 1.017 and 0.006 in this simulation. [BMB: consider removing dotted line (see note elsewhere); on this and prev figure consider removing redundant y-axis label on right panel (and adjusting/squashing interpanel spacing)?] [Ali: ok?]

but only for an unrealistic scenario — very high testing intensities that begin before the epidemic starts. It occurs when waiting people do not isolate ($\theta_w = 0$), and most easily for targeted testing (Fig. 3(b), right three panels of top row) [BMB: can we rule out the possibility that this phenomenon could happen with random testing? In the left panel of Fig. 3, $\theta_w = 0/\theta_c = 0.75$ panel, there is a hint of this behaviour; it looks like the light green [second lightest] region displays this behaviour, but it's hard to see even a maximum magnification]. [Ali: Yes we can rule out this for random testing, (see Eqs. A20 and A21 and the brief analysis followed)] This phenomenon occurs — increasing testing intensity increases \mathcal{R}_0 — because more rapid testing leaves more susceptibles in the "waiting-for-negative-results" category at the DFE; these people must then wait for their tests to be returned (during which time they may become infected) before they can be tested again, receive a positive test, and then begin self-isolating. This effect is usually weak compared to the beneficial effects of testing. [BMB: I am still trying to understand why slowing testing return (decreasing ω) decreases \mathcal{R}_0 over

most of the parameter space considered here, which is a counterintuitive/silly result. Fast test returns help when we have high test positivity and low isolation during the waiting period (specifically, [much] lower isolation while waiting than when confirmed, but I think we're assuming that); we want to get waiting people into the "confirmed" compartment as quickly as possible. Can we understand/explain this result more thoroughly using that logic, and can we argue that what we are looking at is not a realistic parameter range? Does the low baseline \mathcal{R}_0 we are using play into this, e.g. by reducing test positivity? Is there a simple expression for test positivity during the invasion phase?]

Lastly, we show that increasing the focus of testing from random to targeted, always increases Δ, thus decreases R₀. This can be seen in Fig. 2 and Fig. 3. In particular, we realize higher Δ levels, i.e., darker colors in corresponding plotsfacets as we go from panel (a) to panel (b) in the figures. [BMB: this is the same as point 4 above, right? Am I missing something?] [Ali: you are right.]

5 Discussion

1. A potential advantage of slow test reporting ω , result 3;

- Whether increasing ω lowers \mathcal{R}_0 depends on the precise combination of model parameters including ρ , testing strategies represented by compartment-specific testing weights, test sensitivity and specificity, and the level of isolation efficacy. The potential advantage of slow test reporting is in the individual level as opposed to the community level, but seems inapplicable as a strategy. May be this mechanism combined with increasing testing intensity ρ can be considered alongside other prevention methods, eg., social distancing etc, when the transmission is in the exponential-growth phase (in order to increase the generation interval). One reason in favor of prolonging $1/\omega$ is that it is easy to manipulate while increasing ρ can be limited to the resources.
- 2. The counter-vailing effect of per capita testing intensity, ρ , on \mathcal{R}_0 ; The explanation here is that more rapid testing leaves more susceptibles in the "waiting-for-no" S_n category at the DFE and delay them to get to I_c where they are subject to a full isolation, thus no transmission. We are missing out on community-level advantages of fast testing. What is the explanation for having this counter-vailing effect of ρ in targeted testing and not in the random one? May because in the targeted testing more I_u s are tested compared to S_u s, given that higher ω leaves more people in S_n and I_n which results in more transmission. While targeted testing strategies, including targeting people with infection-like symptoms or the contacts of confirmed cases, are always more effective than random testing, as expected, we find that in some cases the direct effect of testing is that viral spread is greater for a slow test than for a fast test. This counter-intuitive effect can occur when people are cautious when awaiting a test result, and may not be robust to second-order effects of fast testing (such as better contact tracing).

- 3. Specifying the compartment-specific relative testing weights, Specifically $\frac{w_I}{w_S}$;
 - More targeted testing is always good in viral control, We incorporated the compartmentspecific relative testing weights, w_S , w_I and w_R , to model random testing and targeted testing strategies. Here, in the case of targeted testing and for the simplicity and illustration purposes, we assumed that infected and recovered individuals are tested at three times the per capita rate of susceptible individuals, thus $w_I/w_S=3$ and $w_R=w_I$. Note that we have not specified a methodology to assign particular relative testing weights corresponding to a particular targeted testing scenario. Modeling different targeted testing strategies, equivalently test-specific testing weights in our framework, requires prior information of the conditional probabilities of getting tested for people in a given compartment. This can be implied when we would like to quantify and compare the effect of different levels of test focus for infectious people on the basic reproduction number \mathcal{R}_0 , and conclude about the disease spread management. For example, when people are tested for "screening", the individuals with potential higher mobility, eg. people who are getting on flights, get more tested and thus the corresponding heavier testing weight is assigned than people awaiting for a surgery and are probably going to stay in a long-term-care facility and consequently less mobile and more isolated to begin with. With our model, we would be able to compare the sensitivity of the disease dynamics, through \mathcal{R}_0 , with respect to testing different high-risk groups in the population. This part needs to be developed further in future work.
- 4. What can we say in the context of strength and speed paradigm?

² References

250 251

253

254

255

256

257

258

259

260

261

262

264

266

268

269

271

- Dietz, K. (1993). The estimation of the basic reproduction number for infectious diseases.

 Statistical methods in medical research, 2(1):23–41.
- Foddai, A., Lubroth, J., and Ellis-Iversen, J. (2020). Base protocol for real time active random surveillance of coronavirus disease (COVID-19)—adapting veterinary methodology to public health. *One Health*, page 100129.
- Keeling, M. J. and Rohani, P. (2011). *Modeling infectious diseases in humans and animals*.

 Princeton University Press.
- Ma, J. and Earn, D. J. D. (2006). Generality of the final size formula for an epidemic of a newly invading infectious disease. *Bulletin of Mathematical Biology*, 68(3):679–702.
- Maplesoft (2010). Maple (14). a division of Waterloo Maple Inc., Waterloo, Ontario.
- R Core Team (2020). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
- Shaw, C. L. and Kennedy, D. A. (2021). What the reproductive number R0 can and cannot tell us about COVID-19 dynamics. *Theoretical Population Biology*.

van den Driessche, P. and Watmough, J. (2002). Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. *Mathematical biosciences*, 180(1-2):29–48.

Appendix

$_{\scriptscriptstyle 1}$ 5.1 Model and calculation of \mathcal{R}_0

290

The model in the form of a system of ordinary differential equations is

$$dS_{\mathbf{u}}/dt = -\Lambda S_{\mathbf{u}} - F_S S_{\mathbf{u}} + \omega S_{\mathbf{n}},\tag{A1a}$$

$$dS_{\rm n}/dt = -(1 - \theta_{\rm w})\Lambda S_{\rm n} + (1 - p_S)F_S S_{\rm u} - \omega S_{\rm n},\tag{A1b}$$

$$dS_{p}/dt = -(1 - \theta_{w})\Lambda S_{p} + p_{S}F_{S}S_{u} - \omega S_{p}, \tag{A1c}$$

$$dS_{c}/dt = -(1 - \theta_{c})\Lambda S_{c} + \omega S_{p}, \tag{A1d}$$

$$dI_{\rm u}/dt = \Lambda S_{\rm u} - F_I I_{\rm u} + \omega I_{\rm n} - \gamma I_{\rm u},\tag{A1e}$$

$$dI_{\rm n}/dt = (1 - \theta_{\rm w})\Lambda S_{\rm n} + (1 - p_I)F_I I_{\rm u} - \omega I_{\rm n} - \gamma I_{\rm n},\tag{A1f}$$

$$dI_{\rm p}/dt = (1 - \theta_{\rm w})\Lambda S_{\rm p} + p_I F_I I_{\rm u} - \omega I_{\rm p} - \gamma I_{\rm p}, \tag{A1g}$$

$$dI_{\rm c}/dt = (1 - \theta_{\rm c})\Lambda S_{\rm c} + \omega I_{\rm p} - \gamma I_{\rm c}, \tag{A1h}$$

$$dR_{\rm u}/dt = \gamma I_{\rm u} - F_R R_{\rm u} + \omega R_{\rm n},\tag{A1i}$$

$$dR_{\rm n}/dt = \gamma I_{\rm n} + (1 - p_R)F_R R_{\rm u} - \omega R_{\rm n}, \tag{A1j}$$

$$dR_{\rm p}/dt = \gamma I_{\rm p} + p_R F_R R_{\rm u} - \omega R_{\rm p},\tag{A1k}$$

$$dR_{\rm c}/dt = \gamma I_{\rm c} + \omega R_{\rm p},\tag{A11}$$

$$dN/dt = \omega(S_{\rm n} + I_{\rm n} + R_{\rm n}),\tag{A1m}$$

$$dP/dt = \omega(I_{\rm p} + R_{\rm p}),\tag{A1n}$$

where parameters are specified in Table 1. The next generation matrix for this model is $G = FV^{-1}$, where matrix F represents the inflow of new infection to the infected compartments and matrix V represents the flow in the infected compartments when the population is totally susceptible. Matrices F and V are

$$F = \beta/N_0 \begin{bmatrix} S_{\rm u}^* & (1 - \theta_{\rm w}) S_{\rm u}^* & (1 - \theta_{\rm w}) S_{\rm u}^* & (1 - \theta_{\rm c}) S_{\rm u}^* \\ (1 - \theta_{\rm w}) S_{\rm n}^* & (1 - \theta_{\rm w})^2 S_{\rm n}^* & (1 - \theta_{\rm w})^2 S_{\rm n}^* & (1 - \theta_{\rm w})(1 - \theta_{\rm c}) S_{\rm n}^* \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \end{bmatrix}$$
(A2)

$$= \beta/N_0 \begin{bmatrix} S_{\rm u}^* \\ (1 - \theta_{\rm w})S_{\rm n}^* \\ 0 \\ 0 \end{bmatrix} \begin{bmatrix} 1, 1 - \theta_{\rm w}, 1 - \theta_{\rm w}, 1 - \theta_{\rm c} \end{bmatrix}, \text{ and}$$
(A3)

$$V = \begin{bmatrix} \hat{F}_I + \gamma & -\omega & 0 & 0\\ -(1 - p_I)\hat{F}_I & \omega + \gamma & 0 & 0\\ -p_I\hat{F}_I & 0 & \omega + \gamma & 0\\ 0 & 0 & -\omega & \gamma \end{bmatrix}.$$
 (A4)

The matrix inverse of V is

292

293

294

295

296

301

302

303

307

309

$$V^{-1} = \frac{1}{\gamma C} \begin{bmatrix} \gamma(\omega + \gamma)^2 & \gamma\omega(\omega + \gamma) & 0 & 0\\ \gamma(\omega + \gamma)(1 - p_I)\hat{F}_I & \gamma(\omega + \gamma)(\hat{F}_I + \gamma) & 0 & 0\\ \gamma(\omega + \gamma)p_I\hat{F}_I & \gamma\omega p_I\hat{F}_I & C\gamma/(\omega + \gamma) & 0\\ \omega(\omega + \gamma)p_I\hat{F}_I & \omega^2 p_I\hat{F}_I & C\omega/(\omega + \gamma) & C \end{bmatrix}, \quad (A5)$$

where $C = (\gamma(\omega + \gamma) + (\gamma + \omega p_I)\hat{F}_I)(\omega + \gamma)$ and \hat{F}_I is the *per capita* testing rate for the infected people and represented in Eq. (5). Note that all the columns of matrix V^{-1} summ up to $1/\gamma$.

The particular form of F with two rows of zeros at the bottom results in the following blocked form of matrix G.

$$G = \left[\begin{array}{cc} G_{11} & G_{12} \\ 0 & 0 \end{array} \right],\tag{A6}$$

where both blocked matrices G_{11} and G_{12} are 2 by 2. Given the upper triangular form of matrix G, the basic reproduction number \mathcal{R}_0 (defined as the spectral radius of matrix G) is only determined by the blocked matrix G_{11} ,

$$G_{11} = \frac{\beta}{\gamma C} \begin{bmatrix} (\omega - \rho)/\omega \\ (1 - \theta_{\rm w})\rho/\omega \end{bmatrix} \begin{bmatrix} 1, 1 - \theta_{\rm w}, 1 - \theta_{\rm w}, 1 - \theta_{\rm c} \end{bmatrix} \begin{bmatrix} \gamma(\omega + \gamma)^2 & \gamma\omega(\omega + \gamma) \\ \gamma(\omega + \gamma)(1 - p_I)\hat{F}_I & \gamma(\omega + \gamma)(\hat{F}_I + \gamma) \\ \gamma(\omega + \gamma)p_I\hat{F}_I & \gamma\omega p_I\hat{F}_I \\ \omega(\omega + \gamma)p_I\hat{F}_I & \omega^2 p_I\hat{F}_I \\ (A7) \end{bmatrix}.$$

It is notable that matrix F (A2) has rank one and consequently G_{11} does so. That is G_{11} has only one non-zero eigenvalue which is \mathcal{R}_0 .

The expression of \mathcal{R}_0 has a complicated form with all of the model parameters involved. This expression can be simplified and represented given the specific form of matrix G_{11} (A7). For the purpose of simplicity we present \mathcal{R}_0 in the manuscript in terms of expressions C, C1 and C2, specified in (8).

It remains hard to show that the reproduction number \mathcal{R}_0 is decreasing with respect to per capita testing intensity, ρ , and the speed of the test return, ω , for the feasible ranges of the parameters, that is

$$\omega > 0, \tag{A8}$$

$$0 \le \rho < \omega, \tag{A9}$$

$$0 \le \theta_{\rm w} \le \theta_{\rm c} \le 1,\tag{A10}$$

$$\frac{w_I}{w_S} \ge 1. \tag{A11}$$

In realistic cases the testing rate ρ is very small (i.e., only a small fraction of the population can be tested every day); it is thus reasonable to use a linear approximation of \mathcal{R}_0 for $\rho \ll 1$ to analyze the behaviour of \mathcal{R}_0 with respect to ω (see section 5.3). In the next section we provide an equivalent representation of \mathcal{R}_0 in order to show that increasing testing intensity typically decreases \mathcal{R}_0 .

5.2 More testing intensity may decrease \mathcal{R}_0

This section shows that $\frac{\partial \Delta}{\partial \rho}$ can be positive or negative, with Δ defined in Eq. (8), and thus $\frac{\partial \mathcal{R}_0}{\partial \rho} < 0$, where \mathcal{R}_0 is given in Eq. (6). We rewrite matrix G_{11} in (A7) in the following form to simplify the calculations:

$$G_{11} = \frac{\beta}{\gamma C} \left[\begin{array}{c} S_{\rm u}^*/N_0 \\ (1 - \theta_{\rm w}) S_{\rm n}^*/N_0 \end{array} \right] \left[C - C_1, C - C_2 \right], \tag{A12}$$

where C is the same as the one in Eq. (8), i.e.,

$$C = (\omega + \gamma)(\gamma(\omega + \gamma) + (\omega p_I + \gamma) \hat{F}_I),$$

and C_1 and C_2 are

$$C_1 = (\omega + \gamma)(\theta_{\mathbf{w}} \gamma + \theta_{\mathbf{c}} \omega p_I)\hat{F}_I,$$

$$C_2 = (\omega \gamma (1 + p_I)\hat{F}_I + \gamma^2 (\omega + \gamma + \hat{F}_I))\theta_{\mathbf{w}} + \omega^2 p_I \hat{F}_I \theta_{\mathbf{c}},$$

where \hat{F}_I is given in Eq. (5). Note that for analysis brevity, we let $N_0 = 1$, thus $S_{\rm u}^*$ and $S_{\rm n}^*$ are in the scale of 0 to 1. \mathcal{R}_0 is in the same form as in Eq. (6)

$$\mathcal{R}_0 = \frac{\beta}{\gamma} (1 - \Delta),$$

where

316

321

$$\Delta = \frac{1}{C} (C_1 S_{\rm u}^* + (C_2 (1 - \theta_{\rm w}) + C \theta_{\rm w}) S_{\rm n}^*).$$

The first goal is to explore how changes in isolation, $\theta_{\rm w}$ and $\theta_{\rm c}$, affects \mathcal{R}_0 . Mathematically we would like to verify the sign of $\frac{\partial \mathcal{R}_0}{\partial \theta_{\rm w}}$ and $\frac{\partial \mathcal{R}_0}{\partial \theta_{\rm c}}$. We start with simplifying Δ (5.2) by factoring $\theta_{\rm w}$ and $\theta_{\rm c}$ in Eq. (5.2). Thus, Δ can be rewritten as

$$\Delta = \frac{1}{C} \Big(-D_1 S_{\mathrm{n}}^* \boldsymbol{\theta}_{\mathrm{w}}^2 + \Big(-\omega^2 p_I \hat{F}_I S_{\mathrm{n}}^* \boldsymbol{\theta}_{\mathrm{c}} + D_2 S_{\mathrm{n}}^* + \gamma \hat{F}_I(\omega + \gamma) \Big) \boldsymbol{\theta}_{\mathrm{w}} + (\omega + \gamma S_{\mathrm{u}}^*) \omega p_I \hat{F}_I \boldsymbol{\theta}_{\mathrm{c}} \Big), \tag{A13}$$

where

$$D_1 = (\omega + \gamma)\gamma^2 + (\omega + \gamma + \omega p_I)\gamma \hat{F}_I, \tag{A14}$$

$$D_2 = (3\omega + 2\gamma)\gamma^2 + (\omega + \gamma + 2\omega p_I)\gamma \hat{F}_I + (\gamma + p_I \hat{F}_I)\omega^2.$$
 (A15)

 Δ , Eq. (A13), is linear in θ_c with a positive coefficient. thus

$$\frac{\partial \Delta}{\partial \theta_c} = 1/C(\gamma S_u^* + \omega (1 - \theta_w S_n^*)) \omega p_I \hat{F}_I. \tag{A16}$$

This results in increasing Δ , thus decreasing \mathcal{R}_0 with respect to θ_c , that is $\frac{\partial \mathcal{R}_0}{\partial \theta_c} \leq 0$. Note that C is independent of θ_c and θ_w .

With a similar logic, Δ (A13) is a concave-down quadratic equation in $\theta_{\rm w}$, given by

$$1/C\left(-D_1 S_{\mathrm{n}}^* \boldsymbol{\theta}_{\mathrm{w}}^2 + \left(-\omega^2 p_I \hat{F}_I S_{\mathrm{n}}^* \boldsymbol{\theta}_{\mathrm{c}} + D_2 S_{\mathrm{n}}^* + \gamma \hat{F}_I(\omega + \gamma)\right) \boldsymbol{\theta}_{\mathrm{w}}\right). \tag{A17}$$

We show that the feasible range of $\theta_{\rm w}$ lies between 0 and the vertex of this parabola where the parabola is increasing in $\theta_{\rm w}$, and so does Δ which results in inferring $\frac{\partial \mathcal{R}_0}{\partial \theta_{\rm w}} \leq 0$. It is enough to show that partial derivative of the expression (A17) with respect to $\theta_{\rm w}$ at $\theta_{\rm w}=1$ is non-negative. It follows that

$$\frac{\partial \Delta}{\partial \theta_{\mathbf{w}}} \Big|_{\theta_{\mathbf{w}}=1} = 1/C \Big((D_2 - 2D_1 - \omega^2 p_I \, \hat{F}_I \, \theta_{\mathbf{c}}) \, S_{\mathbf{n}}^* + \gamma \, \hat{F}_I(\omega + \gamma) \Big)$$

$$= 1/C \Big((\gamma(\omega + \gamma) + \gamma \omega^2 + (1 - \theta_{\mathbf{c}}) \omega^2 p_I \, \hat{F}_I) \, S_{\mathbf{n}}^* + \gamma(\omega + \gamma) \, \hat{F}_I \, (1 - S_{\mathbf{n}}^*) \Big),$$
(A18)

which is a positive quantity, given that θ_c and S_n^* vary between 0 and 1.

The second goal is to explore how changes in per capita testing intensity ρ affects \mathcal{R}_0 . Mathematically we would like to verify the sign of $\frac{\partial \mathcal{R}_0}{\partial \rho}$, which specifically depends on $\frac{\partial \Delta}{\partial \rho}$. We use the derived expressions for $S_{\rm u}^*$ and $S_{\rm n}^*$, given by Eqs. (4), in Δ (5.2). Also, we define $\phi = \hat{F}_S = \frac{\rho \omega}{\omega - \rho}$, to reparameterize ρ . This is mainly to avoid singularity in \hat{F}_I (5), when testing intensity ρ is very close to the rate of test return ω . Thus, ρ is reparameterized as

$$\rho = \frac{\omega \phi}{\omega + \phi}.\tag{A19}$$

This one-to-one monotonic reparameterization enables us to simplify the mathematical expressions and explore the simpler $\frac{\partial \Delta}{\partial \phi}$ instead of the complicated $\frac{\partial \Delta}{\partial \rho}$. The derivative is

$$\partial \Delta / \partial \phi = \frac{1}{d_3} (a_3 \phi^2 + b_3 \phi + c_3), \tag{A20}$$

where

324

$$a_{3} = \frac{w_{I}}{w_{S}} \left((1 - \theta_{w}) \left(1 + \frac{w_{I}}{w_{S}} \right) \theta_{w} \gamma^{3} + (1 - \theta_{c}) p_{I}^{2} \theta_{w} \frac{w_{I}}{w_{S}} \omega^{3} \right)$$

$$+ \left(\left((1 - \theta_{w} - \frac{w_{I}}{w_{S}}) \theta_{c} + (3 - 2\theta_{w}) \theta_{w} \frac{w_{I}}{w_{S}} \right) p_{I} + (1 - \theta_{w}) \left(1 + \frac{w_{I}}{w_{S}} \right) \theta_{w} \right) \omega \gamma^{2}$$

$$+ \left(\left((1 - \theta_{w} - \theta_{w} \frac{w_{I}}{w_{S}}) \theta_{c} + (2 - \theta_{w}) \theta_{w} \frac{w_{I}}{w_{S}} \right) p_{I} + (2 \theta_{w} - \theta_{w}^{2} - \theta_{c}) \frac{w_{I}}{w_{S}} p_{I}^{2} \right) \omega^{2} \gamma \right),$$

$$b_{3} = 2 \frac{w_{I}}{w_{S}} (\omega + \gamma) \gamma \left((\omega + \gamma + \omega p_{I}) (2 - \theta_{w}) \gamma \theta_{w} + (1 - \theta_{w}) \omega^{2} p_{I} \theta_{c} + \omega^{2} p_{I} \theta_{w} \right),$$

$$c_{3} = (\omega + \gamma)^{2} \gamma \left((2 - \theta_{w}) \gamma^{2} \theta_{w} + (1 + \frac{w_{I}}{w_{S}}) \omega \gamma \theta_{w} + \frac{w_{I}}{w_{S}} \omega^{2} p_{I} \theta_{c} \right),$$

$$d_{3} = \frac{(\omega + \gamma)}{\omega} \left((\omega p_{I} + \gamma) \frac{w_{I}}{w_{S}} \phi + (\omega + \gamma) \gamma \right)^{2} (\omega + \phi)^{2}.$$

Note that $\phi \geq 0$, also b_3 , c_3 and d_3 are all positive. However a_3 can be positive or negative. If $a_3 \geq 0$, $\partial \Delta/\partial \phi \geq 0$ for all feasible range of parameters, thus $\frac{\partial \mathcal{R}_0}{\partial \rho} \leq 0$. It is straight forward to show that $a_3 \geq 0$ in case of random testing strategy, i.e., $w_S = w_I = 1$. If $a_3 < 0$, then the quadratic expression in the numerator of (A20) has a positive root, ϕ^* , such that for $\phi > \phi^*$, $\partial \Delta/\partial \phi < 0$.

An example of this counter-vailing effect of ϕ , and consequently ρ , on \mathcal{R}_0 occurs when $\theta_{\rm w} = 0$ and $\theta_{\rm c} = 1$. This is illustrated in the top-right panel of the Fig. 3 panel (b), where the strength of isolation for awaiting people is the least, but the most for the confirmed cases. In this case, simplifying a_3 in Eq. (A21) gives

$$a_3 = \frac{w_I}{w_S} \omega \gamma p_I((\omega + \gamma) - \frac{w_I}{w_S}(\omega p_I + \gamma)).$$

Specifically, in the case of targeted testing which is identified by $\frac{w_I}{w_S} > 1$, and using a perfect sensitive test, thus $p_I = 1$, there exists a range for ρ over which $\frac{\partial \mathcal{R}_0}{\partial \rho} \leq 0$. Note that ρ and ω have a similar mechanism in delaying people to get into I_c , thus we would expect to see the non-trivial counter-vailing effect of these two parameters on \mathcal{R}_0 .

5.3 rate of returning tests

The third goal is to explore how changes in the rate of test return ω affects \mathcal{R}_0 . Mathematically we would like to verify the sign of $\frac{\partial \mathcal{R}_0}{\partial \omega}$, which specifically depends on $\frac{\partial \Delta}{\partial \omega}$. We use the linearization of \mathcal{R}_0 around $\rho = 0$ to show that there a non-monotonic relationship between \mathcal{R}_0 and ω . The Taylor expansion of Δ at $\rho = 0$ is

$$\Delta = \frac{\rho}{\omega \gamma(\omega + \gamma)} \left(\frac{w_I}{w_S} \omega^2 p_I \theta_c + \left(\frac{w_I}{w_S} + 1 \right) \gamma \omega \theta_w + \gamma^2 \theta_w (2 - \theta_w) \right). \tag{A22}$$

This results in

337

346

348

350

351

353

$$\frac{\partial \Delta}{\partial \omega} = \frac{\rho}{\omega^2 (\omega + \gamma)^2} \left(\left(p_I \frac{w_I}{w_S} \theta_c - \left(1 + \frac{w_I}{w_S} \right) \theta_w \right) \omega^2 + 2\theta_w \gamma (\theta_w - 2) \omega + \theta_w \gamma^2 (\theta_w - 2) \right), \quad (A23)$$

around $\rho = 0$.

5.4 On Testing Rate and Numerical Singularity

In this work, we didn't do any numerical solutions for the trajectories in our analysis. However, if one tries to do so there would be a singularity issue to deal with. Specifically, the numerical singularity issue with the chosen σ (1) is that the population in S compartments appeared to blow up when the DFE is achieved. This is once the only untested people are susceptibles, the FOI will become $\Lambda = 0$, testing rate $F_s = \rho N_0/S_u$. Thus, the first equation of the model (A1) will become $dS_u/dt = -\rho N_0 + \omega S_n$. Thus changes in S_u will be no longer dependent on S_u with a linear rate of leaving the S_u compartment. IN fact the testing rate, σ , should be formulated such that people from the untested compartments will not be tested if they are not there. One way to fix this issue, is to consider a maximum testing rate, τ (1/day). In general, we want to test at a rate of ρ across the whole population. This won't always be possible, so we impose a maximum rate of τ per testable person and redefine $\sigma = \frac{\tau \rho N_0}{\tau W + \rho N_0}$, with the assumption that $\tau \gg \rho$. This alteration in σ , does not change any results related to \mathcal{R}_0 , thus we only impose it in the simulation of the epidemic dynamic.

${f 5.5}$ The effect of testing focus parameter ${w_I \over w_S}$ on ${\cal R}_0$

We define $w_{\rm IS} = \frac{w_I}{w_S}$.

$$\frac{\partial \Delta}{\partial w_{\rm IS}} = \frac{(\omega - \rho) \left(\omega(\omega - \rho\theta_{\rm w}) + \gamma(\omega - \rho)\right) \left(\theta_{\rm w}\gamma + \theta_{\rm c}\omega p_{\rm I}\right)}{\left(-\omega^2 \gamma + \omega \gamma \rho - \gamma \rho \omega w_{\rm IS} - \omega \gamma^2 + \gamma^2 \rho - \omega^2 p_{\rm I} \rho w_{\rm IS}\right)^2},\tag{A24}$$

which is a positive quantity. Thus, $\frac{\partial \mathcal{R}_0}{\partial w_{\rm IS}} \leq 0$. Therefore, increasing the focus of testing on the infectious people will result in less transmission.